Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.4.3.13 (
lysyl oxidase
)
1,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prostaglandin E2, transforming growth factor-beta, and interleukin-1 beta variably regulate the expression of
cyclooxygenase 1
, cyclooxygenase 2, and
lysyl oxidase
in IMR90, human embryo lung fibroblasts. Prostaglandin E2 at 100 nM upregulates
cyclooxygenase 1
mRNA by approximately three-fold while it downregulates
lysyl oxidase
mRNA levels. Notably, prostaglandin E2 suppresses the enhancing effect of TGF-beta on basal levels of
lysyl oxidase
mRNA. These changes in steady state mRNA levels reflect transcriptional level control, at least in part. Corresponding changes are seen in the protein levels of
lysyl oxidase
,
cyclooxygenase 1
and cyclooxygenase 2 and catalytic activities of these enzymes, including net prostaglandin E2 synthesis. Cyclooxygenase 2 mRNA(t1/2, 30 min) is considerably less stable than that of
cyclooxygenase 1
(t1/2, 4 h) while
lysyl oxidase
mRNA is unusually stable (t1/2 > 14 h). Taken together with the differing kinetics with which these genes respond to perturbation by these cytokines, the present results suggest a coordinated, autocrine-like mechanism of regulation of
cyclooxygenase 1
and cyclooxygenase 2 and further point to the potential of their metabolic product, prostaglandin E2, to suppress the expression of
lysyl oxidase
in the inflammatory response to injury.
...
PMID:Regulation of lysyl oxidase and cyclooxygenase expression in human lung fibroblasts: interactions among TGF-beta, IL-1 beta, and prostaglandin E. 887 12
